No Data
Fractyl Health (GUTS.US) GLP-1 gene therapy can prevent the rebound when stopping semaglutide.
Fractyl Health, which focuses on developing new methods for obesity and type 2 diabetes, reported the latest data on its preclinical GLP-1 gene therapy Rejuva at the 84th American Diabetes Association (ADA) Scientific Sessions.
BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating
BofA Securities analyst Jason Gerberry maintains $Fractyl Health(GUTS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.8% and a total average return of -0.8% ove
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
Express News | Fractyl: Expects Open Label Data From Reveal-1 Cohort in Q4,Mid-Point Analysis for Remain-1 in 2025
Express News | Fractyl Health: Will Accelerate Revita Weight Maintenance Clinical Study Remain-1
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
No Data